Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?
- 31 March 2008
- journal article
- review article
- Published by Elsevier in Journal of Autoimmunity
- Vol. 30 (1-2) , 63-67
- https://doi.org/10.1016/j.jaut.2007.11.001
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- BAFF‐modulated repopulation of B lymphocytes in the blood and salivary glands of RITUXIMAB‐TREATED patients with Sjögren's syndromeArthritis & Rheumatism, 2007
- Balancing diversity and toleranceThe Journal of Experimental Medicine, 2005
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Excess BAFF Rescues Self-Reactive B Cells from Peripheral Deletion and Allows Them to Enter Forbidden Follicular and Marginal Zone NichesImmunity, 2004
- Predominant Autoantibody Production by Early Human B Cell PrecursorsScience, 2003
- The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosusArthritis & Rheumatism, 2003
- An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent PathwayScience, 2001
- Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivityNature Immunology, 2001
- Baff Mediates Survival of Peripheral Immature B LymphocytesThe Journal of Experimental Medicine, 2000
- BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell GrowthThe Journal of Experimental Medicine, 1999